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ThE REmOdELINg Of LEfT ATRIUm ANd vAsOdILATION fAcTORs 
chANgEs IN IschEmIc hEART fAILURE
V. I. Denesyuk, О. V. Denesyuk, N. O. Muzyka
NatioNal Pirogov MeMorial Medical UNiversity, viNNytsІa, UkraiNe
Background. According to the national registries of European countries and epidemiological studies, the 
prevalence of chronic heart failure (CHF) among adults is 2,0–5,0%, and increases due to age, in people aged 
over 70 years old it is 10,0–20,0%.
Objective. to find out the specific features of remodeling of the left atrium and change of vasodilation 
factors in ischemic heart failure with reduced and preserved left ventricular ejection fraction and to establish 
correlation relationships.
Methods. A full clinical examination of 153 patients with CHF (105 men and 48 women) was conducted to 
achieve this objective. The surveyed patients underwent clinical examinations; spectrophotometric parameters: 
quantification of markers of vasodilation, metabolites of monoxide nitrogen — nitrates and nitrites with gris 
reagent; content of endothelial nitric oxide synthase (eNos) in serum — elisa for the set of Nitric oxide synthase 
3, Endothelial (NOS3) Human ELISA Kit (Cloud-Clone Corp, USA). Electrocardiographic (ECG) examination was 
conducted in 12 standard conventional leads on electrocardiograph by the Hungarian production Heart Screen 
112 D. 
Results. The 1st group of the examined patients with reduced lv eF prevails iii (significant) degree la dilatation 
in 33 (70.21%) cases, II (moderate) degree of LA dilatation was determined in 14 (29.78%), and I (initial) degree 
was not defined at all. in the 2nd group of the patients with preserved LV EF mainly the II degree of LA dilatation 
was determined in 44 (44.51%) cases, and decreased LA dilation in 39 (36.79%) cases (p<0.01), and III degree 
of la dilation was defined in 23 (21.69%) cases (p<0.01). in patients with stable coronary heart disease, complicated 
by heart failure with reduced LV EF and II degree of LA dilatation, eNOS levels in the serum was 449.00±39.91 pg/ml, 
whereas in patients with stable coronary heart disease, complicated by heart failure with preserved LV EF and II 
stage of la dilatation — 673.56±50.98 pg/ml (p<0.01). at iii stage of la dilatation in patients of the 1st group level 
eNOS was 344.20±51.98 pg/ml in the patients of the 2nd group — 616.90±36.49 pg/ml (p<0.01). at the same 
degree and with LA dilation in the patients of the 2nd group eNOS was 750.27±99.85 pg/ml. 
Conclusions. The structural and functional changes of the left atrium and changing factors of vasodilation 
in patients with stable coronary artery disease of II-III functional classes complicated by heart failure of I–III 
functional classes are studied. It is established that in the examined patients with stable coronary heart disease 
complicated by heart failure with reduced left ventricular ejection fraction mainly iii (significant) degree of 
dilatation of the left atrium was determined, while in patients with stable coronary heart disease, complicated 
by heart failure with preserved left ventricular ejection fraction mainly II (moderate) degree of dilation of the left 
atrium was determined. In comparison with the results of research among the patients with stable coronary 
heart disease, complicated by heart failure with reduced left ventricular ejection fraction, and a group of patients 
with preserved left ventricular ejection fraction, it was determined a significant decrease in eNos, nitrites, total 
amount of nitrites and nitrates.
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Introduction
According to the national registries of 
european countries and epidemiological stu-
dies, prevalence of chronic heart failure (CHF) 
among adults is 2.0–5.0%, and increases in 
proportion to age, people aged over 70 years 
it is from 10.0 to 20.0% [16]. Considering demo-
graphic trends, in Ukraine as well, to increase 
the number of population of older age groups, 
the provision of medical care to patients with 
CHF is becoming a topical issue [2, 14].
Distinguish systolic and diastolic options of 
CHF. In version of systolic CHF the presence of 
clinical signs in patients with ejection fraction 
(EF) of LV≤45.0%, at diastolic version with LV 
eF>45.0% is observed [4]. It is known that left 
ventricular hypertrophy (lvH) precedes the 
development of CHF and is formed together 
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with or even is caused by this disease. Analysis 
of prognostic value of lvH in patients with CHF 
with preserved ejection fraction proves that the 
high risk of lethal outcome is observed in 
patients with left ventricular myocardial mass 
that exceeds 400 g [3]. It is established that at 
the progression of diastolic dysfunction an 
increased risk of sudden cardiac death in 80.0% 
occurs [4, 15]. endothelial dysfunction is very 
important in development of CHF. The cause of 
nitric oxide (NO) synthesis inhibition by endo-
thelium as a major component of its dysfunction 
at CHF is free radical stress [11]. The main cause 
of CHF is negative impact of free radical factors 
that leads to lower ventricular myocardial 
contractile function followed by entire body 
hypoxia, endothelial dysfunction with the 
appropriate activation of cellular factors [17]. 
These processes can lead to increasing of blood 
coagulation capacity, which is one of the causes 
of thrombotic complications in patients with 
CHF [12]. Biosynthesis of NO from l-arginine 
occurs in three major isoforms of NO-synthase, 
two constitutive: neuronal (nNOS) and endo­
thelial (eNOS), and inducible one (iNOS) [6].
The objective of the study is to find out 
the specific features of left atrium remodeling 
and vasodilation factors changes in case of 
ischemic heart failure with reduced and 
preserved left ventricular ejection fraction and 
to establish correlation relationships.
Material and Methods
To achieve this objective a full clinical 
examination of 153 patients with CHF (105 men 
and 48 women) was conducted; they were 
treated in the Department of Cardiology for 
patients with arrhythmias of vinnitsa Regional 
Centre of Cardiovascular Disorders (Ukraine). 
All patients were divided into 2 groups: group 
1 consisted of patients with stable coronary 
heart disease complicated by heart failure with 
reduced lv eF (n=47); group 2 — patients with 
stable coronary heart disease complicated by 
heart failure with preserved lv eF (n=106). The 
control group consisted of 30 healthy individuals. 
The diagnoses of CH and FC was made due to 
clinical, laboratory and instrumental criteria, as 
recommended by the european Society of 
Cardiology (2012) and the Association of 
Cardiologists of Ukraine (2012) [16]. Diagnosis 
and treatment of clinical forms of coronary 
artery disease were made by order of the 
Ministry of Health of Ukraine № 152 from 
03.02.2016 [9]; functional class (FC) CH — by 
NYHA classification.
The criteria for inclusion. Patients with stable 
coronary artery disease II-III FC followed by CHF 
II-III FC on informed consent to participate in 
the study. Exclusion criteria: CHF FC IV by the 
NYHA; period up to 3 months from the begin-
ning of acute myocardial infarction, or stroke; 
implanted artificial pacemaker or need of im­
plantation; severe diseases of respiratory 
system, kidneys, liver with hepatic insufficiency, 
anaemic state of haemoglobin 90,0 g/dl and 
below; the formation of malignant disorders 
and severe neuro-psychiatric disorders. 
Among the patients who participated in the 
study mail prevailed. The average age of pa-
tients was 68.80±0.90 years. Hypertension was 
defined in 132 (86.27%) patients. Systolic blood 
pressure (BP) was 142.40±5.01 mm Hg, diastolic 
blood pressure — 88.30±2.95 mmHg
The examined patients underwent clinical 
(complaints, case history, physical examination); 
laboratory tests (general clinical blood and 
urine tests, blood glucose, bilirubin, cholesterol, 
β­lipoprotein, creatinine, urea, coagulation 
para meters); spectrophotometric parameters: 
quantification of vasodilation markers meta bo­
lites of monoxide nitrogen: nitrates and nitrites 
with Gris reagent; content of endothelial nitric 
oxide synthase (eNOS) in serum — elISA for 
the set of Nitric Oxide Synthase 3, endothelial 
(NOS3) Human elISA Kit (Cloud-Clone Corp, 
USA). electrocardiographic (eCG) examination 
was conducted in 12 standard conventional 
leads on electrocardiograph Heart Screen 112 
D made in Hungary. Statistical analysis was 
performed with standard statistical package 
STATISTICA 6.0. For primary analysis of tables 
and intermediate calculations Microsoft excel 
package was used.
Results and Discussion
The decrease in left atrium (lA) dilation 
degree in patients with stable coronary heart 
disease complicated by heart failure with 
reduced and preserved lv eF is presented in 
Table 1.
In Table 1 the 1st group of the examined 
pa tients with reduced lv eF prevails III (sig-
nificant) degree of LA dilatation in 33 (70.21%) 
cases, II (moderate) degree of lA dilatation in 
14 (29.78%), I (initial) degree is not defined at 
all. In the 2nd group of patients with preserved 
lv eF the de gree of dilatation II lA was deter-
mined in 44 (44.51%) cases, and slightly de-
creased degree of lA dilation in 39 (36.79%) 
cases (p<0,01), III de gree of lA dilation in 23 
(21,69%) cases (p<0,01).
V. I. denesyuk et al.
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Remodeling of myocardium, including 
hypertrophy and dilation of left ventricle with 
a changes of its geometry and a contraction 
violation precedes clinical skim CHF manifes-
tations [7]. Thus, remodeling is a harbinger of 
heard activity decompensation [7, 13]. The 
features of myocardial remodeling are studied 
the most in patients after myocardial infarction 
with heart failure development [7, 8, 14].
These results are consistent with the data 
that myocardial ischemia may be accompanied 
by its dysfunction [7]. 
The study of factors of vasodilation levels 
and degrees of lA dilatation in patients with 
stable coronary heart disease complicated by 
heart failure with reduced and preserved lv eF 
is presented in Table 2.
In patients with stable coronary heart 
disease complicated by heart failure with 
reduced lv eF and II degree of lA dilatation, 
eNOS levels in the serum is 449.00±39.91 pg/ml, 
whereas in patients with stable coronary heart 
disease complicated by heart failure with pre-
served lv eF and II stage of lA dilatation — 
673.56±50.98 pg/ml (p<0.01). At III stage of lA 
dilatation in patients of group 1 the eNOS level 
is 344.20±51.98 pg/ml in patients of groups 
2 — 616.90±36.49 pg/ml (p<0,01). At the same 
degree and with lA dilation in patients of group 
2 eNOS is 750.27±99.85 pg/ml. Thus, in the 
examined patients with the progression of 
heart failure the endothelial factors decrease, 
e.g. eNOS.
In the study of levels of metabolites of 
nitrogen monoxide — nitrites and nitrates in 
blood serum the following data were obtained: 
in patients with stable coronary heart disease, 
complicated by heart failure with reduced lv 
eF and II and III stage of lA dilatation, the total 
level of nitrates and nitrites in serum was 
significantly lower than in patients with stable 
coronary heart disease, complicated by heart 
failure with preserved lveF and II and III stage 
of lA dilatation (p<0.01).
Among the patients of group 1with reduced 
lv eF with the progression of lA dilation degree 
from II (moderate) stage to III (large) one, eNOS 
levels in blood serum decreased by 23.34%. 
Table 1. Remodeling of left atrium in case of stable coronary heart disease complicated  
by heart failure with reduced and preserved left ventricular ejection fraction
The degree o f dilation lA
Patients with heart failure 
with reduced lv eF group 1, 
n=47
Patients with heart failure 
with preserved lv eF group 2, 
n=106
p
I (initial) lA from  
40.0 to 45.0 mm
0 39 (36.79 %) р<0,01
II (moderate) lA from  
45.1 mm to 50.0 mm
14 (29.78%) 44 (41.51%)* р<0,01
III (significant) LA from  
50.1 mm and more
33 (70.21%)* 23 (21.69%) р<0,01
Notes: LA — the size of the left atrium; * p<0.01 — reliable change index.
Table 2. Vazodilating factors at different stages of left atrium dilation in case of stable  
coronary heart disease complicated by heart failure with reduced and preserved  
left ventricular ejection fraction (M±m)
Indices
Patients with heart failure with 
reduced lv eF group 1, n=47
Patients with heart failure with preserved lv eF 
group 2, n=106
II degree of lA 
dilatation 
n=14
III degree of lA 
dilatation 
n=33
I degree of lA 
dilation 
n=39
II degree of lA 
dilatation 
n=44
III degree of lA 
dilatation 
n=23
eNOS, pg/ml 449.00±39.91 344.20±51.98 750.27±99.85 673.56±50.98* 616.90±36.49#
Nitrite+nitrate, 
mmol/l
16.75±0.75 16.05±0.94 19.27±0.67 19.22±0.77* 19.05±1.10#
Nitrite, mmol/l 4.41±0.21 3.95±0.32 5.15±0.20 5.06±0.16* 5.30±0.37#
Nitrate, mmol/l 12.34±0.59 12.09±1.13 14.11±0.61 14.16±0.71* 13.74±0.85
Notes:
* — comparison of patients with stable coronary heart disease complicated by heart failure with reduced lv eF and 
preserved lv eF and II degree of left atrium dilatation (p<0,01);
# — comparison of patients with stable coronary heart disease complicated by heart failure with reduced lv eF and 
preserved lv eF and III degree of left atrium dilatation (p<0,01).
V. I. denesyuk et al.
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Among the patients of group 2 with preserved 
lv eF with the progression of lA dilatation from 
I (initial) stage to II one, the level of eNOS in 
blood serum decreased by 12.89%, and with the 
progression of the II stage to III one lA dilation 
reduced by 8.41%.
In the examined patients with stable 
coronary artery disease complicated by heart 
failure with reduced left ventricular ejection 
fraction, the correlation analysis between 
indicators of linear dimensions of lA and eNOS 
levels in the blood serum a direct correlation of 
medium strength (r=0.38) (p<0,01) was esta b-
lished. Carrying out a similar correlation ana ly-
sis for patients with stable coronary heart di-
sease complicated by heart failure with pre-
served lv eF also allowed to establish a direct 
correlation of weak force (r=0.21) (p<0.01).
Progressive hypertrophy and dilatation of 
heart was followed by subsequent first diastolic 
disruption and then systolic ventricular dysfunc-
tion, increased myocardial oxygen demand, 
changes in subendocardial blood flow, myo­
cardial bioenergy disorders and increased risk 
of life-threatening ventricular arrhythmias [1].
Recent research proved instrumental and 
morphological parallels, so we expand on the 
remodeling of heart as a single clinical and 
morphological syndrome that is important for 
making prognosis in patients with coronary 
heart disease [18]. 
The processes of LA remodeling are defined 
by the degree of new myocardial damage and 
the presence of viable myocardium.
Conclusions
In patients with stable coronary heart 
disease complicated by heart failure with 
reduced left ventricular ejection fraction III 
(significant) degree of left atrium dilatation was 
mainly determined, while in patients with stable 
coronary heart disease complicated by heart 
failure with preserved left ventricular ejection 
fraction II (moderate) degree of left atrium 
dilation was mainly determined.
In the patients with stable coronary heart 
disease complicated by heart failure with 
reduced left ventricular ejection fraction in 
comparison with the group of patients with 
preserved left ventricular ejection fraction, the 
significant reduction of eNOS, nitrites, total of 
nitrites and nitrates was defined during the 
study.
The research allowed to establish the direct 
correlation of medium strength (r=0.38) between 
parameters of linear left atrial size and eNOS 
levels in blood serum of the patients with stable 
coronary artery disease complicated by heart 
failure with reduced left ventricular ejection 
fraction (p<0.01) and the direct correlation of 
weak force (r=0.21) in the examined patients 
with stable coronary artery disease complicated 
by heart failure with preserved left ventricular 
ejection fraction (p<0,01).
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